Nomenclature of GES-type extended-spectrum beta-lactamases.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Mechanistic basis for inhibition of the extended-spectrum β-lactamase GES-1 by enmetazobactam and tazobactam.FEBS letters · 2025
   Article
2. A Sustainable Combined Approach to Control the Microbial Bioburden in the School Environment.Microorganisms · 2025
   Article
3. Challenges in laboratory diagnosis and antibiotic treatment options for a newly described Pseudomonas aeruginosa class A beta-lactamase type GES-62 strain.GMS infectious diseases · 2025
   Article
4. RAC: Repository of Antibiotic resistance Cassettes.Database : the journal of biological databases and curation · 2011
   Article
5. Integron mobilization unit as a source of mobility of antibiotic resistance genes.Antimicrobial agents and chemotherapy · 2009
   Article
6. Carbapenemases: the versatile beta-lactamases.Clinical microbiology reviews · 2007
   Review
7. Beta-lactamase nomenclature.Antimicrobial agents and chemotherapy · 2006
   Review
8. First outbreak of Klebsiella pneumoniae clinical isolates producing GES-5 and SHV-12 extended-spectrum beta-lactamases in Korea.Antimicrobial agents and chemotherapy · 2005
   Article
9. Integron-encoded GES-type extended-spectrum beta-lactamase with increased activity toward aztreonam in Pseudomonas aeruginosa.Antimicrobial agents and chemotherapy · 2005
   Article

Corrections and comments

• Comment on
  GES-2, a class A beta-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem.2001
• Comment on
  Nosocomial spread of ceftazidime-resistant Klebsiella pneumoniae strains producing a novel class a beta-lactamase, GES-3, in a neonatal intensive care unit in Japan.2004
• Comment on
  Molecular characterization of a cephamycin-hydrolyzing and inhibitor-resistant class A beta-lactamase, GES-4, possessing a single G170S substitution in the omega-loop.2004

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as